Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
Plus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma patients who received ...
read at Endpoints ↗Neutral
September 25, 2026 10:34 AM EDTUpdated 11:19 AM News Briefing Legend's five-year data suggests Carvykti could be a cure; Addex and Indivior split up ENDPOINTS Plus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that